Protocol Ledger

Academic / Institutional Sponsor · Consolidated Sponsor Hub

Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest: Clinical Trials & FDA Approval Profile

Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest (Global / Institutional) sponsors 43 reconciled interventional Phase II and Phase III ClinicalTrials.gov studies (2018 to 2026), including 22 active protocols (10 recruiting now), 19 completed protocols, and 0 all-time original FDA Drugs@FDA NDA and BLA approvals.

Primary Focus: Oncology and Hematology Interactive Workbench: Open Full Annual Timeline & Compare ->
Track in Studio / Generate Client Brief ->
Early-Stop Rate vs National (13.8%)4.7%
Median Closed Enrollment vs National (145 pts)40 participants

Verified Sponsor Execution & Regulatory Ledger

Reconciled ClinicalTrials.gov v2 & Drugs@FDA Metrics for Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Sponsor MetricVerified Count / Rate
Phase II & III Protocols (2018 to 2026)43
Active Pipeline (Recruiting Now)22 (10)
Completed vs Stopped Early19 / 2 (4.7%)
Median Closed Actual Enrollment40 participants
Physical Hospital Site Disclosure100.0% named hospitals
FDA Drugs@FDA Original NDA/BLA Approvals0 (0 since 2018)

Top Partner U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Partnered With Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Hospital Research SiteLocationShared Protocols
Universitätsklinikum UlmUlm11
Medizinische Hochschule HannoverHanover10
Universitätsklinikum LeipzigLeipzig9

Indexed Multi-Center Phase II & III Protocols

Representative ClinicalTrials.gov v2 Studies Sponsored by Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
NCT IdentifierProtocol Brief TitlePhaseStatus
NCT06856837- IKF/AIO-QUINTIS - Evaluating Fruquintinib in Combination With Tislelizumab in Microsatellite Stable / Proficient Mismatch Repair (MSS/pMMRPhase IIRECRUITING
NCT07387198Neoadjuvant Merkel Cell Carcinoma Therapy (Tx) With the PD-1 Inhibitor CemiplimabPhase IIRECRUITING
NCT06440993Durvalumab + Intraductal Radiofrequency Ablation (ID-RFA) in Extra- and Intrahepatic CholangiocarcinomaPhase IIRECRUITING
NCT07176312Zanidatamab in Combination With Pembrolizumab and Chemotherapy in HER2 and PD-L1 Positive Metastatic Gastroesophageal Adenocarcinoma (GEA) PPhase IIRECRUITING
NCT07260175Phase II Study Evaluating Ivosidenib Maintenance After SOC Adjuvant Chemotherapy in Curative mIDH1 CholangiocarcinomaPhase IIRECRUITING

Explore interactive annual charts and M&A subsidiary rollups in the Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest Interactive Dossier, benchmark peers in Oncology and Hematology, or review the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI